Therapy-Related Acute Myeloid Leukemia Following TCHP Chemotherapy in Two HER2+ Breast Cancer Patients.
breast cancer
breast cancer outcomes
carboplatin
docetaxel
pertuzumab
t-aml
t-mds
tchp
trastuzumab
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
07 Dec 2020
07 Dec 2020
Historique:
entrez:
11
1
2021
pubmed:
12
1
2021
medline:
12
1
2021
Statut:
epublish
Résumé
Increased risk for the development of therapy-induced myeloid leukemia following the treatment of breast cancer has typically been associated with the use of regimens containing anthracyclines or alkylating agents. We present two cases of estrogen receptor-positive/progesterone receptor-positive/human epidermal growth factor receptor 2-positive (ER+/PR+/HER2+) breast cancer patients, treated with a non-anthracycline, non-alkylating regimen of trastuzumab, carboplatin, docetaxel, and pertuzumab (TCHP), who developed therapy-related acute myeloid leukemia (t-AML) within 30 months of the completion of treatment. Both patients had marked cytogenetic abnormalities, including deletions of chromosomes 5 and 7, and highly aggressive disease that resulted in a poor prognosis. While platinum and taxane-based chemotherapy regimens have been previously linked to the development of t-AML or therapy-related myelodysplastic syndrome (t-MDS) following treatment for ovarian cancer, they have not yet been shown to increase the risk of t-AML/t-MDS after their use for breast cancer therapy. As TCHP is widely used for the treatment of HER2/neu overexpressed breast cancer, these cases highlight the need to further evaluate the link between taxane and platinum-based chemotherapeutics for breast cancer and the development of t-AML/t-MDS.
Identifiants
pubmed: 33425535
doi: 10.7759/cureus.11957
pmc: PMC7785496
doi:
Types de publication
Case Reports
Langues
eng
Pagination
e11957Informations de copyright
Copyright © 2020, Gill et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Int J Gynecol Cancer. 2008 Nov-Dec;18(6):1371-6
pubmed: 18217963
Cancer Genet. 2019 Oct;238:69-75
pubmed: 31425928
J Clin Oncol. 2007 Sep 1;25(25):3871-6
pubmed: 17664457
Oncologist. 2020 May;25(5):391-397
pubmed: 32073195
N Engl J Med. 2011 Oct 6;365(14):1273-83
pubmed: 21991949
Int J Gynecol Cancer. 2006 Jan-Feb;16 Suppl 1:236-40
pubmed: 16515597
Cancer. 2018 Mar 1;124(5):899-906
pubmed: 29236294
J Clin Oncol. 2015 Feb 1;33(4):340-8
pubmed: 25534386
Iran J Cancer Prev. 2015 Mar-Apr;8(2):125-8
pubmed: 25960852
Case Rep Oncol Med. 2016;2016:8308179
pubmed: 27057370
JAMA Oncol. 2019 Mar 1;5(3):318-325
pubmed: 30570657
Clin Lymphoma Myeloma Leuk. 2020 Mar;20(3):147-155
pubmed: 31953046